AKBA
Price
$3.97
Change
+$0.28 (+7.59%)
Updated
Jun 6 closing price
Capitalization
971.75M
53 days until earnings call
ATOS
Price
$0.90
Change
+$0.04 (+4.65%)
Updated
Jun 6 closing price
Capitalization
111.06M
71 days until earnings call
Interact to see
Advertisement

AKBA vs ATOS

Header iconAKBA vs ATOS Comparison
Open Charts AKBA vs ATOSBanner chart's image
Akebia Therapeutics
Price$3.97
Change+$0.28 (+7.59%)
Volume$8.18M
Capitalization971.75M
Atossa Therapeutics
Price$0.90
Change+$0.04 (+4.65%)
Volume$646.63K
Capitalization111.06M
AKBA vs ATOS Comparison Chart
Loading...
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ATOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKBA vs. ATOS commentary
Jun 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBA is a Buy and ATOS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 08, 2025
Stock price -- (AKBA: $2.88 vs. ATOS: $0.81)
Brand notoriety: AKBA and ATOS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKBA: 82% vs. ATOS: 62%
Market capitalization -- AKBA: $971.75M vs. ATOS: $111.06M
AKBA [@Biotechnology] is valued at $971.75M. ATOS’s [@Biotechnology] market capitalization is $111.06M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKBA’s FA Score shows that 0 FA rating(s) are green whileATOS’s FA Score has 1 green FA rating(s).

  • AKBA’s FA Score: 0 green, 5 red.
  • ATOS’s FA Score: 1 green, 4 red.
According to our system of comparison, ATOS is a better buy in the long-term than AKBA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKBA’s TA Score shows that 3 TA indicator(s) are bullish while ATOS’s TA Score has 4 bullish TA indicator(s).

  • AKBA’s TA Score: 3 bullish, 4 bearish.
  • ATOS’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both AKBA and ATOS are a bad buy in the short-term.

Price Growth

AKBA (@Biotechnology) experienced а +2.49% price change this week, while ATOS (@Biotechnology) price change was -6.60% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +10.01%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

AKBA is expected to report earnings on Jul 31, 2025.

ATOS is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKBA($972M) has a higher market cap than ATOS($111M). AKBA YTD gains are higher at: 51.579 vs. ATOS (-13.865). AKBA has higher annual earnings (EBITDA): -13.72M vs. ATOS (-29.46M). ATOS has more cash in the bank: 74.8M vs. AKBA (51.9M). ATOS has less debt than AKBA: ATOS (0) vs AKBA (47.6M). AKBA has higher revenues than ATOS: AKBA (160M) vs ATOS (0).
AKBAATOSAKBA / ATOS
Capitalization972M111M876%
EBITDA-13.72M-29.46M47%
Gain YTD51.579-13.865-372%
P/E RatioN/AN/A-
Revenue160M0-
Total Cash51.9M74.8M69%
Total Debt47.6M0-
FUNDAMENTALS RATINGS
AKBA vs ATOS: Fundamental Ratings
AKBA
ATOS
OUTLOOK RATING
1..100
1863
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
27
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10096
PRICE GROWTH RATING
1..100
3560
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATOS's Valuation (27) in the Medical Specialties industry is somewhat better than the same rating for AKBA (75) in the Biotechnology industry. This means that ATOS’s stock grew somewhat faster than AKBA’s over the last 12 months.

ATOS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as AKBA (100) in the Biotechnology industry. This means that ATOS’s stock grew similarly to AKBA’s over the last 12 months.

ATOS's SMR Rating (96) in the Medical Specialties industry is in the same range as AKBA (100) in the Biotechnology industry. This means that ATOS’s stock grew similarly to AKBA’s over the last 12 months.

AKBA's Price Growth Rating (35) in the Biotechnology industry is in the same range as ATOS (60) in the Medical Specialties industry. This means that AKBA’s stock grew similarly to ATOS’s over the last 12 months.

AKBA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ATOS (100) in the Medical Specialties industry. This means that AKBA’s stock grew similarly to ATOS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AKBAATOS
RSI
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 12 days ago
87%
Stochastic
ODDS (%)
Bearish Trend 12 days ago
78%
Bullish Trend 12 days ago
70%
Momentum
ODDS (%)
N/A
Bearish Trend 12 days ago
90%
MACD
ODDS (%)
N/A
Bearish Trend 12 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 12 days ago
87%
Bearish Trend 12 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 12 days ago
84%
Bullish Trend 12 days ago
80%
Advances
ODDS (%)
Bullish Trend 13 days ago
85%
Bullish Trend 26 days ago
80%
Declines
ODDS (%)
Bearish Trend 28 days ago
86%
Bearish Trend 18 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 12 days ago
86%
Bearish Trend 12 days ago
88%
Aroon
ODDS (%)
Bullish Trend 12 days ago
88%
Bullish Trend 12 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ATOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

AKBA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with XERS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then XERS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
-1.37%
XERS - AKBA
42%
Loosely correlated
-1.04%
ADAP - AKBA
41%
Loosely correlated
-3.28%
ATOS - AKBA
40%
Loosely correlated
-3.13%
ABOS - AKBA
40%
Loosely correlated
N/A
FHTX - AKBA
39%
Loosely correlated
+6.17%
More

ATOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATOS has been loosely correlated with ABOS. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ATOS jumps, then ABOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATOS
1D Price
Change %
ATOS100%
-3.13%
ABOS - ATOS
50%
Loosely correlated
N/A
ABCL - ATOS
46%
Loosely correlated
+3.03%
NKTR - ATOS
45%
Loosely correlated
+3.68%
GBIO - ATOS
44%
Loosely correlated
-1.11%
ACHV - ATOS
44%
Loosely correlated
-0.32%
More